Humana Inc, Louisville, KY.
J Manag Care Spec Pharm. 2022 Mar;28(3):379-386. doi: 10.18553/jmcp.2022.28.3.379.
Medication nonadherence in the United States contributes to 125,000 deaths and 10% of hospitalizations annually. The pain of preventable deaths and the personal costs of nonadherence are borne disproportionately by Black, Latino, and other minority groups because nonadherence is higher in these groups due to a variety of factors. These factors include socioeconomic challenges, issues with prescription affordability and convenience of filling and refilling them, lack of access to pharmacies and primary care services, difficulty taking advantage of patient engagement opportunities, health literacy limitations, and lack of trust due to historical and structural discrimination outside of and within the medical system. Solutions to address the drivers of lower medication adherence, specifically in minority populations, are needed to improve population outcomes and reduce inequities. While various solutions have shown some traction, these solutions have tended to be challenging to scale for wider impact. We propose that integrated medical and pharmacy plans are well positioned to address racial and ethnic health disparities related to medication adherence. This study was not supported by any funding sources other than employment of all authors by Humana Inc. Humana products and programs are referred to in this article.
美国的药物不依从导致每年有 12.5 万人死亡和 10%的住院治疗。可预防的死亡的痛苦和不依从的个人成本不成比例地由黑人和拉丁裔以及其他少数族裔承担,因为由于各种因素,这些群体的不依从率更高。这些因素包括社会经济挑战、处方的负担能力和便利性问题、获取药房和初级保健服务的机会有限、难以利用患者参与机会、健康素养限制以及由于医疗系统内外的历史和结构性歧视而缺乏信任。需要解决导致药物依从性下降的驱动因素,特别是在少数族裔群体中,以改善人群结果并减少不平等。虽然各种解决方案已经显示出一些效果,但这些解决方案在扩大影响方面往往具有挑战性。我们提出,综合医疗和药房计划非常适合解决与药物依从性相关的种族和民族健康差距。本研究除了所有作者受雇于 Humana Inc. 外,没有得到任何资金来源的支持。本文中提到了 Humana 的产品和计划。